SLC1A2

Excitatory amino acid transporter 2 · P43004 · SLC1A2 on Sugi Atlas →

79,222 patent compounds predicted against SLC1A2, 44,728 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Leucine (SCHEMBL175940)	0.74	7/20
Leucine (SCHEMBL175941)	0.74	7/20
Leucine (SCHEMBL67322)	0.71	7/20
Leucine (SCHEMBL122270)	0.55	7/20
Leucine (SCHEMBL122271)	0.55	7/20
Leucine (SCHEMBL138874)	0.50	7/20
SCHEMBL30895	1.00	6/20
SCHEMBL71719	1.00	6/20
SCHEMBL136824	0.70	6/20
Leucine (SCHEMBL165422)	0.57	6/20
Aspartic Acid (SCHEMBL135731)	0.52	6/20
SCHEMBL157396	0.41	6/20
Valine (SCHEMBL111113)	0.38	6/20
Glutamic Acid (SCHEMBL24357)	0.72	5/20
Norvaline (SCHEMBL167258)	0.59	5/20
Norvaline (SCHEMBL167259)	0.59	5/20
SCHEMBL39093	0.54	5/20
SCHEMBL125406	0.54	5/20
SCHEMBL148584	0.54	5/20
SCHEMBL21708	0.50	5/20

Clinical trials — most relevant to SLC1A2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Effects of Kuvan on Melatonin Secretion	PHASE4	COMPLETED
Pilot Study: Postoperative Pain Reduction by Pre Emptive N-Acetylcysteine	PHASE4	COMPLETED
Comparing Ketamine and Propofol Anesthesia for Electroconvulsive Therapy	PHASE4	COMPLETED
Pharmacogenetic Treatment With Anti-Glutaminergic Agents for Comorbid PTSD & AUD	PHASE3	COMPLETED
Memantine for Refractory OCD Patients	PHASE3	UNKNOWN
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia	PHASE1/PHASE2	RECRUITING
Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis	PHASE2	UNKNOWN
Study on Amino Acid Uptake in Brain Tumors	PHASE2	UNKNOWN
Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure	PHASE2	UNKNOWN
A Glutamate Transporter GLT1, in the Treatment of Bipolar Disorder	PHASE2	WITHDRAWN
Effect of Sarcosine on Symptomatology, Quality of Life, Oxidative Stress and Glutamatergic Parameters in Schizophrenia	PHASE2	COMPLETED
DAAOI-1 Treatment for Treatment-resistant Schizophrenia	PHASE2	COMPLETED
D-amino Acid Oxidase Inhibition (DAAOI-1) add-on Treatment for Chronic Schizophrenia	PHASE2	COMPLETED
Ketamine Infusion for Obsessive-Compulsive Disorder	PHASE2	COMPLETED
Placebo-Controlled Trial With GlyTI-M Among Children With Attention Deficit Hyperactivity Disorder (ADHD)	PHASE2	COMPLETED
N-acetylcysteine (NAC) for Improving Cognitive Dysfunction in Schizophrenia	PHASE1	COMPLETED
Excitatory Amino Acids and Activated Microglia After Traumatic Brain Injury: a (R)-[11C]PK11195 PET Study	PHASE1	UNKNOWN
Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy	EARLY_PHASE1	ACTIVE_NOT_RECRUITING
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
CRF vs WCRF or PRF-DRG in CLBP of FJ Origin and RFA Failure of MBDR: Central Sensitization and Aberrant Nerve Sprouting	nan	UNKNOWN
A Study of Cases with Abnormal Serum Ammonia in Neonate and Children Attending Assiut University Children Hospital	nan	NOT_YET_RECRUITING
Stem Cell Study of Genetics and Drug Addiction	nan	COMPLETED
The Impact of Pharmacological and Electric Modulation of NMDA Pathway on the Cognitive Flexibility and Volitional Movement Preparation in Patients With Parkinson's Disease	nan	COMPLETED
High Dose Omega-3 Fatty Acids in the Treatment of Sport Related Concussions	nan	COMPLETED
Establishing the Salience of Type 1 Interferon Pathway Blockade in the Central Mechanisms of SLE Related Fatigue	nan	NOT_YET_RECRUITING
sCD163 in ALS Patients	nan	COMPLETED
Potential Synergistic Effect of Combined Blood Flow Restriction Training and Betaine Supplementation on Skeletal Muscle	nan	COMPLETED
Examination of Brain Serotonin Receptors in Patients With Mood Disorders	nan	COMPLETED
SLC13A5 Deficiency Natural History Study - United States Only	nan	ENROLLING_BY_INVITATION
Pharmacogenetic and Neurofunctional Brain Areas Study in Obese Patients With Binge Eating Disorder	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a SLC1A2 binder may also engage these)

Protein	Name	Similarity
P31596	—	1.000	P31596 →
P43006	—	1.000	P43006 →
SLC1A1	Excitatory amino acid transporter 3	0.996	landscape →
P31597	—	0.996	P31597 →
P51907	—	0.995	P51907 →
P51906	—	0.991	P51906 →
O00341	—	0.991	O00341 →
O57321	—	0.990	O57321 →
Q8JZR4	—	0.989	Q8JZR4 →
Q10901	—	0.988	Q10901 →
Q95135	—	0.987	Q95135 →
Q25605	—	0.987	Q25605 →
SLC1A3	Excitatory amino acid transporter 1	0.986	landscape →
O35544	—	0.985	O35544 →
O35921	—	0.985	O35921 →
P46411	—	0.984	P46411 →
P24942	—	0.984	P24942 →
Q21353	—	0.982	Q21353 →
P56564	—	0.981	P56564 →
Q9N1R2	—	0.981	Q9N1R2 →
Q22682	—	0.980	Q22682 →
P48664	—	0.978	P48664 →
Q01345	—	0.975	Q01345 →
Q21751	—	0.975	Q21751 →
P51912	—	0.975	P51912 →
O16452	—	0.973	O16452 →
SLC9A1	Sodium/hydrogen exchanger 1	0.972	landscape →
D3ZJ25	—	0.972	D3ZJ25 →
P55016	—	0.972	P55016 →
P35449	—	0.972	P35449 →